Wir sind mit live! Mehr erfahren

Viking Therapeutics

VKTX

Börsenwert 3,2 Mrd. $

25,17 USD

-2,20

8,04 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

25,15

-0,02

0,08 %

1 Tag

-8,04 %

5 Tage

-10,84 %

1 Monat

-14,74 %

3 Monate

-30,79 %

6 Monate

-29,12 %

Seit Jahresbeginn

-28,94 %

1 Jahr

-27,53 %

5 Jahre

329,52 %

10 Jahre

2.167,57 %

Profil: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Mitarbeiter: 65

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 50 %

Neutral 37,5 %

Negativ 12,5 %

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

Viking Therapeutics, Inc. (VKTX) reached $25.11 at the closing of the latest trading day, reflecting a -8.26% change compared to its last close.

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

Zacks Investment Research

Viking Therapeutics Starts Phase III Development of Obesity Pill

VKTX launches two phase III studies of oral VK2735 for obesity, building on phase II results showing up to 12.2% mean weight loss.

Viking Therapeutics Starts Phase III Development of Obesity Pill

Zacks Investment Research

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

Zacks Investment Research

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

The Motley Fool

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

Analyst opinions and sales projections for weight loss and type 2 diabetes drug VK2735 vary widely, reflecting both promise and uncertainty. VK2735's potential as a dual therapy could drive significant market share gains.

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

The Motley Fool

2 Stocks That Could Soar in Q4

Viking Therapeutics is set to commence key trials for its obesity drug VK2735. Arcutis Biotherapeutics is expanding Zoryve into new indications and age groups.

2 Stocks That Could Soar in Q4

The Motley Fool

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Viking Therapeutics will soon enter phase 3 trials with its weight loss pill candidate. The company's weight loss injection candidate is also in phase 3 trials.

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.53, representing a +2.88% change from its previous close.

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.73, denoting a -2.84% move from the preceding trading day.

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt